How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

HUMANS HAVE never been immune from the pressures of natural selection. Throughout the history of the species circumstances have arisen to give individuals with certain beneficial mutations an ...

Clonal selection is a process proposed to explain how a single B or T cell that recognizes an antigen that enters the body is selected from the pre-existing cell pool of differing antigen ...

A good sum of two good parts. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform a relevant index, or most peers, over a market cycle on a ...